3.4 Combining SM6Met with tamoxifen in a ratio of 20:1 inhibited all three processes implicated in ER+ breast cancer metastasis to a greater extent than that of the standard of care therapy, 4-OH-Tam, alone. This evidence concerns the gene ESR1 and breast carcinoma.